Tomita Naoto, Hattori Yukako, Fujisawa Shin, Hashimoto Chizuko, Taguchi Jun, Takasaki Hirotaka, Sakai Rika, Tateishi Ukihide, Ishigatsubo Yoshiaki
Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan,
Ann Hematol. 2015 Mar;94(3):431-6. doi: 10.1007/s00277-014-2227-5. Epub 2014 Oct 23.
The International Harmonization Project on Lymphoma recommends (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin's and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44 months. Positive and negative post-PET results were obtained in 31 % (11/36) and 69 % (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18 % and 62 %, respectively (P < 0.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82 %), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64 %). The 3-year overall survival rates in the positive and negative post-PET result groups were 44 % and 84 %, respectively (P = 0.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL.
淋巴瘤国际协调项目推荐使用（18）F - 氟脱氧葡萄糖（FDG） - 正电子发射断层扫描（PET）对FDG摄取阳性的淋巴瘤患者（如霍奇金淋巴瘤和弥漫性大B细胞淋巴瘤）的治疗效果进行常规评估。FDG - PET在预测外周T细胞淋巴瘤（PTCL）患者预后方面的作用尚未完全阐明。我们回顾性地确定了一线治疗后（PET检查后）FDG - PET对PTCL患者预后的预测价值。在纳入的36例患者中，16例经组织学诊断为未另行特指的PTCL，20例诊断为血管免疫母细胞性T细胞淋巴瘤。所有患者均接受了含蒽环类药物的根治性化疗方案。PET检查后的图像由当地核医学医师进行视觉评估。存活患者的中位观察期为44个月。PET检查后结果为阳性和阴性的患者分别占31%（11/36）和69%（25/36）。PET检查后结果为阳性和阴性的两组患者3年无进展生存率分别为18%和62%（P < 0.001）。PET检查后结果为阳性的11例患者中有9例出现疾病进展（PD）（阳性预测值为82%），而PET检查后结果为阴性的25例患者中有16例未出现PD（阴性预测值为64%）。PET检查后结果为阳性和阴性的两组患者3年总生存率分别为44%和84%（P = 0.03）。我们的研究结果表明，PET检查后结果可预测PTCL患者的预后。
